Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects

Journal of Clinical Pharmacology

Volumn 54, Issue 6, 2014, Pages 665-674

  Spyker, Daniel A ^a   Voloshko, Polina ^b   Heyman, Eugene R ^b   Cassella, James V ^a  

^a Alexza Pharmaceuticals   (United States)

^b Cardiocore Lab Inc   (United States)

Author keywords

inhalation delivery; loxapine; pharmacodynamics; pharmacokinetics; thorough QT QTc

Indexed keywords

LOXAPINE; MOXIFLOXACIN; PLACEBO; AEROSOL; NEUROLEPTIC AGENT;

ADULT; AEROSOL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OUTCOME ASSESSMENT; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; AGED; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; DRUG EFFECTS; ELECTROCARDIOGRAPHY; HEART RATE; HEAT; INHALATIONAL DRUG ADMINISTRATION; LONG QT SYNDROME; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AEROSOLS; AGED; ANTIPSYCHOTIC AGENTS; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEALTHY VOLUNTEERS; HEART RATE; HOT TEMPERATURE; HUMANS; LONG QT SYNDROME; LOXAPINE; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84899799666     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.257     Document Type: Article

References (22)

1. Heel RC, Brogden RN, Speight TM, Avery GS., Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent. Drugs. 1978; 15: 198-217.
2. Glazer WM., Does Loxapine have "atypical" properties? Clinical evidence. J Clin Psychiatry. 1999; 60: 42-46.
3. International Conference on Harmonisation (ICH) E14 guideline: Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; October 2005. http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/ucm129357.pdf.
4. Spyker DA, Munzar P, Cassella JV., Pharmacokinetics of loxapine following inhalation of a thermally-generated aerosol in healthy volunteers. J Clin Pharmacol. 2010; 50: 169-179, published online 13-Nov-09, http://www.jclinpharm. org/cgi/content/abstract/50/2/169.
5. Deniker P, Loo H, Cottereau MJ., Parenteral loxapine in severely disturbed schizophrenic patients. J Clin Psychiatry. 1980; 41: 23-26.
6. O'Connell RA, Lieberman JA., Parenteral loxapine in acute schizophrenia. Current Therapeutic Research. 1978; 23: 236-242.
7. Petrie WM, Ban TA, Berney S, Fujimori M, Guy W, Ragheb M, Wilson WH, Schaffer JD., Loxapine in psychogeriatrics: a placebo- and standard-controlled clinical investigation. J Clin Psychopharmacol. 1982; 2: 122-126.
8. Moore DF., Treatment of acute schizophrenia with loxapine succinate Loxitane in a controlled study with chlorpromazine. Curr Ther Res Clin Exp. 1975; 18: 172-180.
9. Simpson GM, Cuculic Z., A double-blind comparison of loxapine succinate and trifluoperazine in newly admitted schizophrenic patients. J Clin Pharmacol. 1976; 16: 60-65.
10. Schiele BC., Loxapine succinate: a controlled double-blind study in chronic schizophrenia. Dis Nerv Syst. 1975; 36: 361-364.
11. Wolpert A, White L, Dana L, et al. Clinical pharmacological trial of loxapine succinate. J Clin Pharmacol. 1970; 10: 175-181.
12. Charalampous KD, Freemesser GF, Malev J, Ford K., Loxapine succinate: a controlled double-blind study in schizophrenia. Curr Ther Res Clin Exp. 1974; 16: 829-837.
13. Bishop MP, Gallant DM., Loxapine: a controlled evaluation in chronic schizophrenic patients. Curr Ther Res Clin Exp. 1970; 12: 594-597.
14. Clark ML, Paredes A, Costiloe JP, Fulkerson FG, Wood F., Evaluation of two dose levels of loxapine succinate in chronic schizophrenia. Dis Nerv Syst. 1977; 38: 7-10.
15. Cole JO, Swett C, Campbell C, Trenholm I., Parenteral and oral loxitane in the treatment of schizophrenic disorders. Current Therapeutic Research. 1982; 31: 656-661.
16. Denber HCB., Efficacy of Loxapine administered parenterally and orally to acute and chronic schizophrenic patients. Current Therapeutic Research. 1980; 28: 777-783.
17. Branchey MH, Lee JH, Simpson GM, Elgart B, Vicencio A., Loxapine succinate as a neuroleptic agent: evaluation in two populations of elderly psychiatric patients. J Am Geriatr Soc. 1978; 26: 263-267.
18. Moyano CZ., A double-blind comparison of loxitane-loxapine succinate and trifluoperazine hydrochloride in chronic schizophrenic patients. Dis Nerv Syst. 1975; 36: 301-304.
19. Peterson CD., Seizures induced by acute loxapine overdose. Am J Psychiatry. 1981; 138: 1089-1091.
20. Drolet B, Zhang S, Deschenes D, Rail J, Nadeau S, Zhou Z, January CT, Turgeon J., Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol. 1999; 10: 1597-1604.
21. Kongsamut S, Kang J, Chen XL, Roehr J, Rampe D., A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol. 2002; 450: 37-41.
22. Yap YG, Camm J., Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation. BMJ. 2000; 320: 1158-1159.